Edwards Lifesciences
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
122% more call options, than puts
Call options by funds: $586M | Put options by funds: $264M
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
27% more first-time investments, than exits
New positions opened: 180 | Existing positions closed: 142
17% more capital invested
Capital invested by funds: $31.9B [Q3] → $37.5B (+$5.53B) [Q4]
4.83% more ownership
Funds ownership: 80.2% [Q3] → 85.02% (+4.83%) [Q4]
1% more funds holding
Funds holding: 1,181 [Q3] → 1,198 (+17) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 345 | Existing positions reduced: 497
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
15%
downside
Avg. target
$77
9%
upside
High target
$90
27%
upside
8 analyst ratings
3 positive
38%
4 neutral
50%
1 negative
13%
Barclays Matt Miksic 59% 1-year accuracy 24 / 41 met price target | 27%upside $90 | Overweight Maintained | 13 Feb 2025 |
Canaccord Genuity William Plovanic 48% 1-year accuracy 23 / 48 met price target | 0%upside $71 | Hold Maintained | 13 Feb 2025 |
RBC Capital Shagun Singh 60% 1-year accuracy 40 / 67 met price target | 20%upside $85 | Outperform Reiterated | 12 Feb 2025 |
Piper Sandler Adam Maeder 64% 1-year accuracy 9 / 14 met price target | 3%upside $73 | Neutral Maintained | 12 Feb 2025 |
Evercore ISI Group Vijay Kumar 36% 1-year accuracy 17 / 47 met price target | 3%upside $73 | In-Line Maintained | 12 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic.
Neutral
Business Wire
3 weeks ago
Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operation.
Neutral
Business Wire
1 month ago
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life.
Positive
Zacks Investment Research
1 month ago
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
Positive
Benzinga
1 month ago
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups.
Negative
Zacks Investment Research
1 month ago
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart?
Neutral
Seeking Alpha
1 month ago
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Investors Business Daily
1 month ago
Edwards Beats Fourth-Quarter Forecasts, But Shares Slip
Edwards Lifesciences stock fell slightly late Tuesday after the company kept its outlook for 2025 despite beating fourth-quarter calls.
Positive
Reuters
1 month ago
Edwards Lifesciences beats profit estimate on strength in heart devices
Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.
Charts implemented using Lightweight Charts™